Hepatitis C and liver transplantation: Fibrosis progression and treatment. Or how to improve management;Hépatite C et transplantation hépatique: Histoire naturelle et traitement ou comment améliorer la prise en charge?

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 11, 2006, Pages 1281-1295

  Asselah, Tarik ^a,b   Boudjema, Hamza ^a   Francoz, Claire ^a   Sobesky, Rodolphe ^a   Valla, Dominique ^a   Belghiti, Jacques ^b   Marcellin, Patrick ^a   Durand, François ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

BONE MARROW SUPPRESSION; DISEASE SEVERITY; EUROPEAN UNION; FIBROSIS; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; POSTOPERATIVE CARE; RECURRENT DISEASE; REVIEW; SURVIVAL RATE;

EID: 33845918370     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(06)73536-9     Document Type: Review

References (125)

1. Conférence de Consensus. Traitement de l'hépatite C. Gastroenterol Clin Biol 2002;26:B303-11.
2. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999;30:956-61.
3. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002;36(Suppl 1):S3-20.
4. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32:98-112.
5. Durand F. Hépatite C et transplantation hépatique. Gastroenterol Clin Biol 2002;26:B82-90.
6. Samuel D, Roche B, Feray C. Traitement de l'hépatite C après transplantation hépatique. Gastroenterol Clin Biol 2002;26:B231-7.
7. Berenguer M, Lopez-Labrador FX, Whright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78.
8. Dhumeaux D. L'hépatite C en France. Gastroenterol Clin Biol 2002;26:B133-7.
9. Roudot Thoraval F. Evolution des caractéristiques épidémiologiques de l'hépatite C. Gastroenterol Clin Biol 2002;26:B138-43.
10. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-56.
11. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;26;347:975-82.
13. Asselah T, Boyer N, Marcellin P. Traitement de l'hépatitie C. Encycl Med Chir, Hépatologie 2003,7-015-B-51.
14. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-22.
15. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-20.
16. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-25.
17. Shuhart MC, Bronner MP, Gretch DR, Thomassen LV, Wartelle CF, Tateyama H, et al. Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology 1997;26:1646-52.
18. De Ledinghen V. Histoire naturelle de l'infection par le virus de l'hépatite C. Gastroenterol Clin Biol 2002;26:B9-22.
19. Trinchet JC. Histoire naturelle de l'infection par le virus de l'hépatite C. Gastroenterol Clin Biol 2002;26:B144-53.
20. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
21. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-8.
22. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
23. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-93.
24. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96.
25. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-10.
26. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion associated non-A non-B hepatitis. N Engl J Med 1992;327:1906-11.
27. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-33.
28. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-years multicenter study. Hepatology 2000;32:91-6.
29. Poynard T, Ratziu V, Charlotte F, Goodman Z, Mchutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
30. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22.
31. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, et al. Interferon a for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:585-91.
32. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. Influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001;34:1193-9.
33. Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Ades L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618-24.
34. Asselah T, Martinot M, Boyer N, Marcellin P. Variabilité génétique du virus de l'hépatite C : implications cliniques. Gastroenterol Clin Biol 2000:24:175-84.
35. Martinot-Peignoux M, Marcellin P, Gournay J, Gabriel F, Courtois F, Branger M, et al. Detection and quantitation of serum hepatitis C virus (HCV) RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994;20:676-8.
36. Marcellin P, Akrémi R, Cazals D, Boyer N, Aupérin A, Vidaud D, et al. Genotype 1 is associated with a slower progression of fibrosis in untreated patients with mild chronic hepatitis C. J Hepatol 2001;34:159A.
37. Asselah T, Martinot M, Cazals-Hatem D, Boyer N, Aupérin A, Le Breton V, et al. Hypervariable region 1 quasispecies in hepatitis C virus gentotype 1b and 3 infected patients with normal and abnormal serum alanine aminotransferase levels. J Viral Hepatitis 2002;9:29-35.
38. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
39. Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003;52:1638-43.
40. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-9.
41. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter ? Gut, 2006;55:122-30.
42. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-84.
43. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-6.
44. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-30.
45. Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JY, Simmonds P, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996;24:1041-6.
46. Di Martino V, Saurini F, Samuel D, Gigou M, Dussaix E, Reynes M, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997;26:1343-50.
47. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-6.
48. Nakagawa M, Sakamoto N, Tanabe Y, Tomoyuki K, Itsui Y, Takeda Y, et al. Suppression of hepatitis C virus replication by cyclosporine A is mediated by blockade of ciclophilins. Gastroenterology 2005;129:1031-41.
49. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
50. Rifai K, Sebagh M, Karam V, Saliba F, Azoulay D, Adam R, et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004;41:446-53.
51. Trak-Smayra V, Contreras J, Dondero F, Durand F, Dubois S, Sommacale D, et al. Role of replicative senescence in the progression of fibrosis in hepatitis C virus (HCV) recurrence after liver transplantation. Transplantation 2004;77:1755-60.
52. Berenguer M, Palau A, Benlloch S, De La Coba C, Aguillera V, Rayon M et al. Rejection induced by antiviral therapy in liver transplant recipients : incidence and outcome (abstract). Hepatology 2005;42:331A.
53. Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, et al. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 2004;10:599-606.
54. Belghiti J. Adult living donor liver transplantation: why and how ? Gastroenterol Clin Biol 2002;26:1085-7.
55. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707.
56. Russo MW, Galanko JA, Zacks SL, Beavers KL, Fried MW, Shrestha R. Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C. Am J Transplant 2004;4:1133-8.
57. Thomas HC, Törok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999;32:152-9.
58. Boyer N, Marcellin P. L'interféron pégylé : nouveau progrès dans le traitement de l'hépatite chronique virale C. Gastroenterol Clin Biol 2000;24:767-9.
59. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998;79:2381-91.
60. Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parwsvaz P, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003;52:283-7.
61. Poynard T, Marcellin P, Lee SS, Niederau C, Minuck GS, Ideo G, et al. Randomised trial of interferon a2b plus ribavirin for 42 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of crhonic infection with hepatitis C virus. Lancet 1998;339:1458-92.
62. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alone or in combination with ribavirin as initail treatment for chronic hepatitis C. N Engl J Med 1998;339:1458-92.
63. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
64. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
65. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
66. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
67. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Invest Med 1994;42:660-70.
68. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995;21:1003-10.
69. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, et al. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993;18:1344-9.
70. Duchatelle V, Marcellin P, Giostra E, Bregeaud L, Pouteau M, Boyer N, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 1998;29:20-8.
71. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
72. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
73. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
74. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378-86.
75. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7.
76. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-7.
77. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.
78. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-5.
79. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351:1535-9.
80. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
81. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83:901-9.
82. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29:1870-5.
83. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-6.
84. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001;48:843-8.
85. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
86. Couzigou P. Quality of life of patients with chronic hepatitis C: effect of treatments. Gastroenterol Clin Biol 2002;26:B257-63.
87. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995; 22:364-9.
88. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Holaander A, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis : analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-13.
89. Bronowicki JP. Treatment of hepatitis C virus-related cirrhosis. Gastroenterol Clin Biol 2002;26:B220-4.
90. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
91. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350-5.
92. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-96.
93. Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-21.
94. Castells L, Vargas V, Allende H, Bilbao I, Lazaro JL, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53-9.
95. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-4.
96. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001;7:863-9.
97. Alberti AB, Belli LS, Airoldi A, de Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001;7:870-6.
98. De Vera ME, Smallwood GA, Rosado K, Davis L, Martinez E, Sharma S, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-86.
99. Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-90.
100. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002;8:1000-6.
101. Lavezzo B, Franchello A, Smedile A, David E, Barbui A, Torrani M, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002;37:247-52.
102. Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002;36:1253-8.
103. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-50.
104. Berenguer M, Prieto M, Palau A, Carrasco D, Rayon JM, Calvo F, et al. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004;16:1207-12.
105. Neff GW, O'Brien CB, Cirocco R, Montalbano M, de Medina M, Ruiz P, et al. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004;10:595-8.
106. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669-74.
107. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004;77:190-4.
108. Ghalib R, Levine C, McClelland T, Hollinger B, Stribling R, Box T, et al. Factors predictive of 24 week viral response to peg-IFN alfa 2b plus ribavirin in patients with recurrent hepatitis C after liver transplantation (abstract). Hepatology 2004;38:446A.
109. Mukherjee S, Rogge J, Weaver L, Schafer DF. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis for recurrent hepatitis C after liver transplantation-a single center experience (abstract). Hepatology 2004;38,453A.
110. Biselli M, Andreone P, Gramenzi A, Lorenzini S, Loggi E, Bonvicini F, et al. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and nonresponder patients on a stable immunosuppressive regimen. Dig Liver Dis 2006;38:27-32.
111. Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2B and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005;19:359-65.
112. Todd Stravitz R, Shiffman ML, Sanyal AJ, Luketic VL, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transplant 2004;7:850-8.
113. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection therapy in liver transplant recipients. Liver Transplant 2004;7:859-67.
114. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995;22:1084-9.
115. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005;41:289-98.
116. Yao N, Hesson T, Cable M, Hong Z, Kwong AD, Le HV, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997;4:463-7.
117. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-55.
118. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9.
119. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347-55.
120. Asselah T, Marcellin P. BILN 2061: a major step toward new therapeutic strategies in hepatitis C. J Hepatol 2004;41:178-81.
121. Moradpour D, Blum HE. A primer on the molecular virology of hepatitis C. Liver Int 2004;24:519-25.
122. Abrignani S, Houghton M, Hsu HH. Perspectives for a vaccine against hepatitis C virus. J Hepatol 1999;31:259-63.
123. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6.
124. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6.
125. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005;102:9294-9.